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Abstract: Hypnotic effects of melatonin and melatoninergic drugs are mediated via MT1 and 
MT2 receptors, especially those in the circadian pacemaker, the suprachiasmatic nucleus, which 
acts on the hypothalamic sleep switch. Therefore, they differ fundamentally from GABAergic 
hypnotics. Melatoninergic agonists primarily favor sleep initiation and reset the circadian clock 
to phases allowing persistent sleep, as required in circadian rhythm sleep disorders. A major 
obstacle for the use of melatonin to support sleep maintenance in primary insomnia results from 
its short half-life in the circulation. Solutions to this problem have been sought by developing 
prolonged-release formulations of the natural hormone, or melatoninergic drugs of longer half-
life, such as ramelteon, tasimelteon and agomelatine. With all these drugs, improvements of 
sleep are statistically demonstrable, but remain limited, especially in primary chronic insomnia, 
so that GABAergic drugs may be indicated. Melatoninergic agonists do not cause next-day 
hangover and withdrawal effects, or dependence. They do not induce behavioral changes, as 
sometimes observed with z-drugs. Despite otherwise good tolerability, the use of melatoninergic 
drugs in children, adolescents, and during pregnancy has been a matter of concern, and should 
be avoided in autoimmune diseases and Parkinsonism. Problems and limits of melatoninergic 
hypnotics are compared.
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Introduction
Insomnia is a highly common disorder, which is experienced by almost everybody, at 
least at advanced age, and becomes chronic in about 10% of the population. Because 
of the transient nature of its milder forms, its importance is frequently underrated. On 
the other hand, the treatment of severe sleep disturbances, such as primary chronic 
insomnia, is challenging and frequently complicated by comorbid symptoms.1–3 The 
etiology of insomnia is obviously divergent. It is sometimes related to psychiatric or 
neurologic diseases that may develop already in younger or middle-aged subjects. 
Moreover, it may be acquired as a consequence of neurodegenerative disorders includ-
ing Alzheimer’s disease,4 especially when the circadian pacemaker, the suprachiasmatic 
nucleus (SCN), or its downstream connections are affected.5–7 Circadian rhythm sleep 
disorders (CRSDs) may be present or develop independently of neurodegeneration. 
In particular, familial advanced sleep phase syndrome (FASPS) and delayed sleep 
phase syndrome (DSPS) are characterized by exceptionally short or long spontane-
ous circadian period lengths. Other circadian disorders are related to weak coupling 
with external time cues, eg, in some blind subjects. Typically, CRSDs cause transient 
or periodically occurring forms of insomnia.8–10 For the circadian system, a possible Neuropsychiatric Disease and Treatment 2009:5 342
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mode of intervention is that of favoring synchronization with 
the environment. Apart from bright light in the morning, ie, 
enhancement of  Zeitgeber strength to reinforce coupling with 
light onset, melatonin may be administered in the evening 
to make use of the re-synchronizing, chronobiotic as well as 
sleep onset-promoting properties of this molecular mediator 
of the darkness signal. In fact, melatonin was shown to be 
effective in the treatment of various forms of CRSDs.11–14
While the use of the chronobiotic melatonin in CRSD is 
plausible for mechanistic reasons, its application in other types 
of insomnia does not warrant immediate success, but has been 
worthy of exploration. In neurobiological terms, the actions of 
melatonin on sleep are largely of a chronobiological nature. 
High densities of the membrane-bound, G protein-coupled 
melatonin receptors MT1 and MT2 are found in the SCN, 
where the pineal hormone acts in a dual way, by resetting 
the clock – mainly via MT2 – and by suppressing neuronal 
firing – mainly via MT1.15–19 Leaving aside some complexities 
of the signaling mechanisms,19 the MT1-mediated effects of 
melatonin on the SCN favor sleep initiation especially, but 
perhaps not exclusively via the hypothalamic sleep switch. 
This structure exhibits on-off responses20–22 and suppresses, 
under the influence of melatonin, the wake-related neuronal 
downstream pathways (“off”) and promotes the sleep-related 
ones (“on”).23,24 However, sleep is a complex phenomenon 
that involves numerous brain regions. Melatonin receptors 
have been detected in various parts of the brain, but receptor 
densities are considerably lower than in the SCN.25–28 The 
thalamus has been assumed to be also involved in soporific 
actions of melatonin.29,30 Melatonin receptors are expressed 
in this region, and spindle formation is promoted by the 
indoleamine.29–31 Spindles are characteristics of non-REM 
(rapid eye movement) sleep, and are involved in the transition 
from stage 2 sleep to deeper sleep stages. However, a major 
problem for judging the relative importance compared to the 
primary SCN-mediated effects results from the complexity 
of the neuronal connections. Apart from the thalamocorti-
cal interplay, which is necessary for spindle formation, the 
thalamus also influences the SCN. Inputs to the SCN are 
known from various other brain areas, too, especially from 
the intergeniculate leaflet,30 which is connected to many 
parts of the brain and also receives a photic input.32 At the 
present state of our knowledge, the problem remains as to 
what extent the thalamus and other brain areas may assist 
the SCN by transmitting melatonin-dependent responses, 
and whether SCN-independent actions of melatonin are suf-
ficient for sleep promotion. In individuals with severe SCN 
dysfunction and melatonin deficiency, exogenous melatonin 
was found to be insufficient for substantially mitigating sleep 
difficulties.33 However, SCN destruction, which causes sleep 
fragmentation and losses of circadian rhythmicity, still allows 
spindle formation.30 Another source of complexity results 
from the necessary integration of primarily chonobiotic and 
homeostatic components of sleep regulation. The homeostatic 
mechanism also comprises a circadian component,24,34,35 
and the existence of a separate homeostatic oscillator has 
been proposed.36 The extent of melatonin’s influences on 
homeostatic sleep may deserve further attention. At least, 
melatonin has been reported to be useful under conditions 
of an insufficient homeostatic drive to sleep.37 Despite the 
highly complex interplay of brain areas during sleep, and 
the existence of presumably multiple inputs from melatonin, 
primary and secondary actions have to be distinguished. The 
phase-resetting effects are relatively well understood and a 
participation of the SCN in sleep initiation cannot be denied. 
Melatoninergic actions in other brain areas and their contribu-
tion to sleep require further elucidation. With regard to the 
high receptor density and the knowledge of SCN-mediated 
actions, the influence of melatonin on the circadian pacemaker 
will be the focus of our considerations.
Melatonin differs in its mode of action from other hypnot-
ics such as benzodiazepines and z-drugs (zolpidem, zaleplon, 
zopiclone, eszopiclone), which lead to a more generalized 
central nervous depression via GABAA receptors. Melatonin 
is capable of indirectly influencing GABAergic mechanisms 
involved in sleep-related routes downstream of the SCN.20–22 
Indirect GABAergic effects in other brain areas may, pos-
sibly, play an additional role. Only at strongly elevated 
pharmacological concentrations can melatonin exert more 
generalized sedative or even narcotic effects, which are, how-
ever, mediated by other mechanisms, such as antiexcitatory 
suppression of calcium signaling and inhibition of neuronal 
NO synthase.38 Moreover, melatonin contrasts with benzodi-
azepines and z-drugs with regard to sleep architecture, ie, the 
relative duration of sleep stages (stages 1–4), which differ in 
sleep depth and undergo an ultradian REM/nonREM cycle 
of about 90 minutes duration. While sleep architecture can 
be considerably changed by GABAergic drugs, the ultradian 
cycle is usually poorly influenced by melatonin, perhaps 
because this periodicity is generated by another, the pontine 
sleep switch,39,40 which does not seem to be a major target 
of melatonin. However, melatonin was reported to increase 
REM sleep duration in a subgroup of patients with reduced 
REM sleep.41 In this context, the SCN is, again, not inde-
pendent of inputs from other brain areas, since certain SCN 
neurons were found to fire more rapidly during REM than Neuropsychiatric Disease and Treatment 2009:5 343
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nonREM phases,24 notwithstanding the primarily suppressive 
MT1 signaling. Therefore, these changes within the REM/
nonREM cycle do not reflect direct melatoninergic actions, 
although they are relevant to sleep and may be indirectly 
influenced by the hormone.
In CRSDs, a melatonin surge of relatively short dura-
tion can be sufficient for resetting the circadian clock, at 
least when applied in a suitable phase of the phase-response 
curve. However, in primary chronic insomnia, the major 
obstacle for the use of melatonin as a clinically efficient 
hypnotic drug was assumed to result from its extremely short 
half-life in the circulation, which is mostly in the range of 
20 to 30 minutes, sometimes even less, but maximally about 
45 min.20–22,42 Although a short-acting compound may pro-
mote sleep initiation, it can improve sleep maintenance only 
marginally. Theoretically, this problem has two solutions. 
One is a prolonged-release formulation of melatonin, the 
other the development of long-acting melatoninergic ago-
nists. Both possibilities have been studied and given rise to 
the production of approved or investigative drugs. Their rela-
tive advantages will be discussed and, where appropriate, also 
compared to the nonmelatoninergic, primarily GABAergic, 
hypnotics that are currently in use.
Signaling and pharmacology 
of melatoninergic agonists
At therapeutic doses, the hypnotic actions of melatonin and 
synthetic melatoninergic drugs are mediated by the mem-
brane receptors MT1 and MT2, as outlined above. In addition 
to the first-discovered agonist-dependent decreases in cAMP, 
a more complex system of signaling routes has been identi-
fied that contributes to the cellular effects.19 These include 
phospholipase C activation, in the case of MT2, and control 
of inward rectifier K+ (Kir) channels, with secondary effects 
on voltage-gated Ca2+ channels, by MT1.19 These last actions 
may be particularly relevant to the suppression of neuronal 
firing and, thereby, contribute to sleep induction via the 
hypothalamic sleep switch.
While phase shifting and neuronal suppression in the 
SCN represent a basis of hypnotic actions of all melatonin-
ergic drugs, sleep research literature frequently ignores the 
fact that the membrane-bound melatonin receptors are not 
restricted to the SCN. Even though receptor density may 
be lower in other target tissues or cells, any melatoninergic 
agonist has to be expected to exert additional effects via these 
receptors, eg, in the immune system, the gastrointestinal 
tract, the vasculature, other central nervous structures and 
various hormonal subsystems.18,19,43–45 Therefore, by contrast 
with other hypnotics, any of the melatoninergic drugs is, for 
fundamental reasons, not only a soporific agent, but also a 
regulator of other physiological functions. These additional 
effects, which are frequently disregarded, may not always be 
beneficial, especially in patients suffering from autoimmune 
diseases or Parkinson’s disease (see following sections).
While signaling and distribution of MT1 and MT2 recep-
tors discriminate melatoninergic agonists from GABAergic 
hypnotics, melatonin also differs from its synthetic analogs in 
the spectrum of binding sites. Several other melatonin-binding 
sites beyond the G protein-coupled MT1 and MT2 receptors 
have been identified,19,44,45 which either display negligible affin-
ity to the synthetic analogs, or have not yet been tested. These 
additional binding sites include quinone reductase 2 (formerly 
believed to represent a third membrane receptor), nuclear 
receptors belonging to the retinoic acid receptor superfamily, 
in particular, RORα1, RORα2, RZRα and RZRβ, calcium-
binding proteins such as calmodulin (presumably requiring 
pharmacological levels because of low affinity), calreticulin, 
nuclear calreticulin analogs, and two mitochondrial binding 
sites, one of which is located at the amphipathic ramp of 
complex 1 and displays high affinity to the indoleamine.19,21,43–45 
The majority of synthetic agonists has not been tested for these 
binding sites, with the exception of ramelteon, which has a 
low affinity to quinone reductase 2,46 and does not seem to 
act via calmodulin.21
In addition to its direct actions, melatonin is metabo-
lized to various bioactive compounds, including indolic 
(eg, 5-methoxytryptamine, N-acetylserotonin) and kynuric 
[N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and 
N1-acetyl-5-methoxykynuramine (AMK)] substances and their 
derivatives (Figure 1).43–45 For reasons of chemical dissimilar-
ity, no homologs of these melatonin metabolites can be formed 
from nonindolic drugs. Among the hypnotics tested, only the 
investigative drug β-methyl-6-chloromelatonin might lead to 
some homologous derivatives (Figure 1).47 In conclusion, the 
full spectrum of actions known from melatonin, which also 
comprises various beneficial effects,38,44 cannot be expected to 
be found with nonindolic hypnotics. On the other hand, those 
drugs showing selectivity towards MT1 and MT2 receptors 
also exert effects beyond sleep promotion.
The various melatoninergic agonists tested for soporific 
effects exhibit substantial differences in receptor affinity, 
half-life, metabolism, and contribution of metabolites to 
sleep promotion. Melatonin itself has different affinities 
to human MT1 and MT2 receptors (Ki = 80.7 and 383 pM, 
respectively).21,47 Its physiological half-life in the circula-
tion is, as mentioned, usually less than half an hour, mainly Neuropsychiatric Disease and Treatment 2009:5 344
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because of rapid hepatic 6-hydroxylation by cytochrome 
P450 monooxygenase subforms, in particular, CYP1A2, 
but also CYP1A1 and CYP1B1.48,49 6-Hydroxymelatonin 
is conjugated and excreted. In other tissues, especially 
the brain, melatonin can be metabolized differently.43 
No soporific effects are known from any of melatonin’s 
natural metabolites, except for 5-methoxytryptophol.50 
The sleep-related effects of this compound are presumably 
without physiological significance. However, the indolic, 
partially serotoninergic43 metabolites, 5-methoxytryptamine 
and N-acetylserotonin, should be tested in more detail for 
possible interferences with sleep or wakefulness.
All these considerations are relevant to immediate and 
prolonged-release melatonin as well, with a main difference 
in bioavailability. Among the various formulations used in 
different studies, the brand Circadin® will be particularly 
considered, because of its approval by the European 
Medicines Agency (EMEA). Circadin® has been developed 
by Neurim, Israel and UK (marketing authorization holder) 
and is now also provided by Lundbeck and by Nycomed. In 
April 2007, it received marketing authorization by EMEA 
for the treatment of insomnia in patients aged 55 years and 
over. It was licensed for the combination of improvement of 
sleep quality and next-day feeling. The pharmacokinetics of 
Circadin®, which requires more detailed future investigation, 
has been tested in 8 healthy male subjects receiving 1, 2, 4 or 
8 mg of the prolonged-release formulation at 10 am, either 
in conjunction with fasting or with a standard meal.51 The 
unusual time of administration was obviously chosen to better 
demonstrate the efficacy of the slow-release formulation and 
to avoid interference with the endogenous melatonin peak. 
Normally, melatonin is given shortly (30 minutes) before 
bedtime, according to the time profile of the natural hormone, 
which exhibits, at least, in healthy nonelderly subjects a 
pronounced nocturnal peak. However, the pharmacokinetics 
of melatonin may differ between daytime and nighttime 
hours, according to data from rats which received continuous 
infusions of melatonin.52 This possibility should be consid-
ered in humans, too. Under the conditions tested in humans, 
2 mg led to a shift of Tmax from about 4 pm to about 11.30 
am (without meal) or 12.30 pm (with meal).51 These values 
should not be overinterpreted, since peaks resulting from 
the drug should not be compared with the physiological 
nocturnal maximum. Cmax values, as presented, have to be 
regarded as preliminary, since they showed considerable 
variation among the relatively few volunteers [without 
drug: range 30 to 126 pg/mL (median 51 pg/mL); drug and 
fasting: range 180 to 855 pg/mL (median 393 pg/mL); 
drug with meal: 205 to 1020 pg/mL (median: 390 pg/mL)]. 
In the 24 h-AUC values, a considerable interindividual 
variation was, again, observed [basal: range 150 to 1017 
pg × h/mg (median 375 pg × h/mg); drug and fasting: range 
823 to 4478 pg × h/mg (median 2257 pg × h/mg); drug 
with meal: range 618 to 5252 pg × h/mg (median 2010 
pg × h/mg)]. These data merely show that this melatonin 
formulation causes increases in blood levels, what had to 
be expected, but the improvements in duration of elevated 
bioavailability, compared to immediate-release melatonin, 
are not sufficiently evident from published data. Tmax and 
Cmax values are not suitable for judging the advantage of 
prolonged release. Elimination time has been inferred to be 
the same (t1/2 about 40 to 50 minutes) as with conventional 
melatonin preparations,51 although this may be dose-depen-
dent. In another study on healthy volunteers of both genders, 
aged 55 to 69 years, the effect of food on AUC after 2 mg 
Circadin® revealed only minor changes.51 A major difficulty 
in interpreting the pharmacokinetic data results from the very 
high interindividual variability. This is not uncommon with 
melatonin in general and is usually explained by differences 
in the rapid first-path hepatic metabolism of the hormone. 
Whether this is really so, especially when authors are claim-
ing a more than 80% elimination via 6-hydroxylation and 
conjugation,51 may be debated. Additional variation may 
result from the gut, which is both a source and sink of mela-
tonin,53–56 allows enterohepatic cycling of this compound,55–58 
contains by two orders of magnitude more melatonin than 
the pineal gland,54 and can release melatonin in terms of a 
postprandial response.54,55,59 Gastrointestinal release of mela-
tonin in response to tryptophan was associated with profound 
sleep promoting effects.53 Because of these complexities and 
difficulties concerning pharmacokinetics, the advantages of 
prolonged-release melatonin should be judged rather from 
the effects on sleep.
Sustained-release formulations different from Circadin® 
have been also tested with regard to their pharmakokinetics, 
including coated sugar spheres60 and solid lipid nanopar-
ticles.61 However, their clinical use is not sufficiently estab-
lished, so that they will not be considered here in detail.
Among the synthetic analogs that have been clinically 
tested, the investigative drug β-methyl-6-chloromelatonin 
(LY 156735) is that one most related to melatonin. This 
agonist developed by Eli Lilly also diplays a high affinity 
towards MT1 und MT2 receptors (Ki = 81 pM for MT1 bzw. 
42 pM for MT2). The preferential binding to MT2 is typical 
for the 6-chlorinated melatonin derivatives, and also seen 
with 6-chloromelatonin.47 Because of the substitution at Neuropsychiatric Disease and Treatment 2009:5 346
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C-atom 6, this drug cannot be converted by the respective 
CYP isoforms to 6-hydroxymelatonin and its half-life in the 
circulation is, therefore, extended.47,62 Although β-methyl-6-
chloromelatonin was effective in phase-shifting the circadian 
rhythm and showed sleep latency-reducing properties simi-
lar to those of melatonin, its effects on sleep maintenance 
remained marginal, even at doses of 20 or 100 mg,47,62,63 so 
that this drug will not be further considered in this review.
Much more detailed information is available on a 
structurally dissimilar melatoninergic agonist, ramelteon 
{= Rozerem® = TAK-375 = (S)-N-[2-(1,6,7,8-tetrahy-
dro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide}, 
produced by Takeda Pharmaceuticals Inc. This compound 
has been approved in 2005 by the FDA for treatment of 
insomnia in the USA. After a negative recommendation by 
EMEA,64 Takeda has withdrawn its European marketing 
authorization application in September 2008.65 The affinities 
of ramelteon to MT1 und MT2 receptors (Ki = 14 pM and 
112 pM, respectively) are higher than those of melatonin 
(cf Ki = 80,7 and 383 pM).46,66,67 Contrary to melatonin and 
other indolic analogs, such as N-acetylserotonin, it does not 
bind to quinone reductase 2, at therapeutic doses (Ki = 2.65 
µM; cf melatonin: Ki = 24 pM).46 It displays very moderate 
binding to the serotonin receptor 5-HT1A (Ki = 5.6 µM), but 
virtually none to other 5-HT receptor subtypes. Numerous 
other receptors, eg, for neurotransmitters, neuropeptides 
including endorphins have been tested and reported to have 
no substantial affinity.67 However, other melatonin binding 
sites, as mentioned above, have not been investigated.
Pharmacokinetics and metabolism of ramelteon have been 
studied in detail. It is rapidly taken up, reaching Tmax between 
0.75 and 0.94 h, over a considerable dose range.68 Its half-life 
in the circulation amounts to about 1 to 2 h and is, therefore, 
considerably longer than that of melatonin.68 After escalating 
doses of 4, 8, 16, 32, and 64 mg, Cmax values of 1.15, 5.73, 
6.92, 17.4, and 25.9 ng/mL, and AUC values of 1.71, 6.95, 
9.88, 22.5, and 36.1 ng × h/mL were obtained.68 Because of 
its structural dissimilarity, the metabolism of ramelteon funda-
mentally deviates from that of melatonin.21,43,47,68 Although it is 
substrate to cytochrome P450 enzymes, including the melatonin-
hydroxylating CYP1A2, the products are substantially different. 
Four metabolites formed by CYP1A2, CYP2C and CYP3A are 
usually referred to as M-I, M-II, M-III und M-IV. Apart from 
cleavage of the tetrahydrofuran ring in M-I, hydroxylations and 
oxidations take place in positions not accessible in melatonin, 
either at a C-atom corresponding to the nitrogen in melatonin’s 
pyrrole ring (M-III, M-IV) or at C-atom 2 of the propionyl 
residue of the aliphatic side chain (M-II, M-IV) (Figure 1).43,47 
Because of the absence of a pyrrole ring, no kynuric metabolism 
is possible in the case of ramelteon.43,47
The properties of metabolite M-II are rather unusual and 
substantially contribute to the pharmacological activity of the 
parent compound. This is not particularly surprising, since 
M-II differs from ramelteon only by the hydroxyl group 
in the aliphatic side chain. On the one hand, this change 
reduces the affinities to MT1 und MT2 receptors by a factor 
of about 10, but, on the other hand, M-II itself is much less 
metabolized, has a half-life 2 to 5 h longer than the parent 
compound and can attain concentrations by 20- to 100-fold 
higher than ramelteon.68 Therefore, any pharmacokinetic con-
sideration of ramelteon cannot be made without considering 
the long-lasting contribution of M-II. Consequently, judg-
ments on the time course of action should not be restricted 
to Tmax, Cmax and AUC values of ramelteon alone.
Another newly introduced synthetic melatoninergic 
agonist is tasimelteon (= N-{[(1R,2R)-2-(2,3-dihydro-1-
benzofuran-4-yl)cyclopropyl]methyl}propanamide = VEC-
162; earlier research codes: BMS-214778 and MA-1). This 
investigative drug is produced and being further developed 
by Vanda Pharmaceuticals, under license from Bristol-
Myers Squibb Co. Binding and pharmacokinetic properties 
in humans have been disclosed only in part, although the 
company may possess more detailed information. According 
to unpublished information cited elsewhere,69 tasimelteon is 
selective for MT1 and MT2 receptors. In a web appendix, the 
following affinity data were presented: pKi = 9.45 ± 0.04 
(0.35 nM) for MT1, and pKi = 9.8 ± 0.07 (0.17 nM) for MT2,70 
without experimental details. After single oral doses between 
10 and 100 mg, mean Tmax values varied from 1.9 to 3.0 h, 
mean Cmax from 59.1 to 417.1 ng/mL, and AUC from 171.1 
to 1916.1 ng × h/mL, however, with considerable interindi-
vidual deviations.70 More detailed pharmacokinetic data have 
been presented for rats and monkeys (Macaca fascicularis).71 
These data indicate rapid uptake (monkeys, at moderate dose, 
Tmax in the range of 1 h) and longer half-life than melatonin 
(t1/2 about 2 to 3 h). A longer half-life mentioned elsewhere, 
without precise values,72 may have referred to the human. The 
metabolism, studied in rat, monkey and human liver, showed 
degradation by CYP1A1, CYP1A2, CYP2D6, and CYP2C9, 
and also some conjugation with glucuronic acid.71,73 Most of 
the metabolites have only been partially characterized and are, 
again, nonhomologous to those of melatonin (Figure 1), for 
fundamental reasons. Properties and kinetics of the tasimelt-
eon metabolites are either unknown or not disclosed.
Agomelatine {= Valdoxan® = N-[2-(7-methoxynaphth-
1-yl)ethyl]acetamide = S20098}, developed by Servier, is Neuropsychiatric Disease and Treatment 2009:5 347
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also an agonist at MT1 and MT2 receptors (Ki = 61.5 pM and 
268 pM, respectively), but additionally acts as a 5-HT2C recep-
tor antagonist (IC50 = 270 nM), with low affinities to other 
5-HT receptor subforms.21,43,47,74 5-HT2C inhibition is largely 
responsible for the additional antidepressant action of this drug. 
The metabolism involving CYP1A1, CYP1A2, and CYP2C9 
is partially different from that of melatonin (Figure 1). One 
main metabolite (S22153) is hydroxylated at the second 
ring carrying the long side chain, another one demethylated, 
corresponding to the formation of N-acetylserotonin from 
melatonin. The demethylated compound (S21517) resembles 
serotonin with regard to the presence of the hydroxyl group 
and, in fact, displays affinity to 5-HT2C.21,43 Since agomelatine 
is not exclusively a melatoninergic drug, it should not be 
regarded simply as a sleep-promoting compound suitable for 
treating an average insomniac, but may be of specific value 
in depressed patients. In February 2009, Valdoxan® was 
approved by EMEA for the treatment of major depressive 
episodes (MDE) in adults,75 but not generally as a hypnotic 
agent. Therefore, it will not be discussed here in any detail, 
despite its undoubtedly existing soporific actions.
Efficacy of melatoninergic hypnotics
All drugs mentioned in the previous section have been tested 
for their soporific potential. First of all, one has to distinguish 
between sleep-promoting effects in patients with CRSDs 
and others suffering from primary chronic insomnia. Any 
of the melatoninergic drugs is effective in phase-shifting 
circadian rhythms and, thus, seems suitable for treating jet 
lag and CRSDs, at least from the hypnotic point of view, 
but not necessarily under aspects of long-term safety.21,22,47,69 
Since acute phase shifting and facilitation of sleep onset are 
also achieved by immediate-release melatonin, advantages 
of prolonged-release melatonin or longer-acting synthetic 
analogs should rather be sought in the treatment of primary 
chronic insomnia. β-Methyl-6-chloromelatonin was only 
marginally efficient in sleep maintenance,47,63,63 and, in terms 
of published evidence, tasimelteon has been only tested after 
artificial light-dark shifts.69 For reasons mentioned, the use 
of agomelatine should be only considered in conjunction 
with depression. Therefore, it seems primarily important to 
compare prolonged-release melatonin, such as Circadin®, and 
its synthetic analog, ramelteon (Rozerem®), with a focus on 
primary chronic insomnia.
Studies on prolonged/extended-release melatonin have 
been conducted in the past using different preparations, 
sometimes referred to as controlled, sustained or slow 
release. Different doses had been used and some formulations 
contained combinations fast (1 mg) and controlled-release 
components (4 mg).76 The different studies are highly diverse, 
frequently of exploratory nature, or related to various disor-
ders. Trials on larger numbers of subjects were only based 
on subjective measures. As compared to study design and 
detailed information on other hypnotics, the evidence is 
often circumstantial and sometimes contradictory. A concep-
tual diversity is even apparent in the material summarized 
by EMEA on Circadin®.51 This material includes various 
exploratory and extended studies, including a phase III trial. 
The larger clinical studies on Circadin®,51,77,78 conducted on 
several hundred elderly patients (55 years and older) with 
primary insomnia are randomized, placebo-controlled and 
double-blind, but not generally with crossover design, and 
mainly based on questionnaires only (Leeds Sleep Evalu-
ation Questionnaire = LSEQ; sometimes also Pittsburgh 
Sleep Quality Index = PSQI, WHO-5 well being index, and 
Clinical Global Improvement scale = CGI). Taken together 
with exploratory studies also using polysomnography 
(PSG) or wrist actigraphy,51,79 the data collectively show 
that prolonged-release melatonin/Circadin® significantly 
reduces sleep onset latency (SOL), whereas direct evidence 
for the support of sleep maintenance and total sleep time is 
poor. Changes in awakenings from sleep are sometimes not 
statistically demonstrable, but may be deduced from patients’ 
reports on improvements of sleep quality.51,77,78 More direct 
support, based on objective measures, for this important 
aspect of primary insomnia would be welcome. It should 
be also mentioned that the percentage of nonresponders to 
melatonin was substantial.51 In this context, the improve-
ments obtained by the prolonged-release formulation should 
be decisive. Reductions in sleep latency are well known 
for fast-release melatonin, and have to be also expected for 
prolonged-release pills, especially as the amounts required 
for promoting sleep initiation are relatively low.80,81 Since the 
development of prolonged-release melatonin was aiming to 
support sleep maintenance, especially in patients with pri-
mary chronic insomnia, the most relevant parameters should 
be reductions in number or duration of awakenings from sleep 
and improvements of total sleep time. To convincingly dem-
onstrate efficacy in sleep maintenance, more data on objective 
measures are required. However, there is a good reason for 
assuming that improvements in sleep quality and efficiency 
will be also demonstrable according to hard criteria, insofar 
as the subjective improvements were particularly evident in 
patients with severe or very severe forms of primary insomnia 
as well as in a subpopulation of poor melatonin secretors, 
as identified by low urinary 6-sulfatoxymelatonin levels.51,78 Neuropsychiatric Disease and Treatment 2009:5 348
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Therefore, Circadin® or other prolonged-release formulations 
of melatonin may be suitable for replacement therapy, eg, in 
patients with age-related decreases in nocturnal melatonin 
secretion.
Additional information on prolonged-/controlled-release 
melatonin is available from studies on treatment jet lag, 
shift work and various disorders, sometimes including 
comparisons with fast-release melatonin. In jet lag,80–82 not 
unexpectedly, either formulation proved to be effective. 
A meta-analysis of 10 studies revealed, however, a supe-
riority of fast-release melatonin.81 A study on aircrews on 
transatlantic flights, based on both subjective measures and 
wrist actigraphy, reported a relatively good efficacy of 2 mg 
sustained-release melatonin.82 In addition to reductions in 
sleep latency, improvements concerning number and duration 
of awakenings after sleep onset, quality of sleep and facilita-
tion of returning to sleep were demonstrated.
Studies on simulated shift work83,84 were affected by the 
problem of melatonin administration in unfavorable circa-
dian phases and are, thus, difficult to compare. The efficacy 
of sustained-release melatonin was also studied in children 
and young adults with CRSDs76,85 and with neurodevelop-
mental disabilities.76,86–94 Improvements were reported, but 
data on sleep initiation were either not provided or, in part, 
insufficient. The clearest results were obtained in the most 
recent study using 5 mg controlled-release melatonin tab-
lets.86 With this higher dosage, reductions in sleep latency 
and rises in night-time sleep duration were demonstrated by 
both subjective measures and wrist actigraphy. In children 
with autism, an open-label study, based on the Children’s 
Sleep Habits Questionnaire and diary, improvements were 
obtained with controlled-release melatonin.95 Some circum-
stantial evidence for sleep improvements were reported for 
depressed patients,96,97 but without changes in the Hamilton 
Rating Score for Depression.97 Positive results were also 
obtained in intensive-care patients with chronic obstructive 
pulmonary disease or pneumonia.98 In a subpopulation of 
schizophrenics, improvements of sleep were reported,99 but 
not after sleep disturbance by the so-called first night effect 
in a sleep laboratory.100 Although some smaller studies 
indicated sleep improvements by melatonin in patients with 
Alzheimer’s disease, as previously summarized,6 neither 
2.5 mg4 nor 6 mg101 sustained-release nor 10 mg immedi-
ate-release4 melatonin resulted in statistically significant 
improvements, perhaps an indication for the heterogeneity 
of these populations.
Compared to prolonged-release melatonin, the outcome 
of trials on ramelteon is much more uniform, as becomes 
evident from recent summaries.20–22,102,103 Collectively, all 
the data unanimously show that ramelteon, at doses of 4 or 
8 mg, not only reduces sleep onset latency, but also improves 
total sleep time and sleep efficiency/sleep quality. This has 
also been demonstrated in several double-blind, placebo-
controlled studies on a total of more than a thousand adult or 
elderly subjects with primary chronic insomnia.104–107 All the 
effects were statistically significant, but the improvements 
of sleep maintenance remained moderate. In accordance 
with the higher receptor affinities of ramelteon compared 
to melatonin, no further improvements were obtained with 
16 or 32 mg daily.105,107 Moreover, ramelteon did not worsen 
sleep apnea,108 in accordance with the lack of generalized 
central nervous suppression, as would occur with GABAergic 
agonists. According to the available data for recommended 
doses (usually 8 mg), ramelteon seems to be somewhat more 
effective than prolonged-release melatonin in the treatment 
of primary chronic insomnia, as far as sleep maintenance is 
concerned. Several factors should contribute to this finding: 
(i) higher receptor affinities to both melatonin receptors, espe-
cially to MT1; (ii) higher bioavailability because of longer 
half-life; (iii) a long-lasting contribution of the metabolite 
M-II; and (iv) the higher recommended doses of 4 or 8 mg 
ramelteon vs 2 mg Circadin®. Nevertheless, EMEA found 
the efficacy of ramelteon in improving sleep maintenance 
insufficient for a marketing authorization.64
Safety, tolerability, withdrawal
In full agreement with numerous findings on immediate-
release melatonin, all studies on the prolonged-release 
formulation unanimously show that the recommended dose 
does not cause next-day hangover, but rather favors morning 
alertness – although some exceptions have been described 
in other investigations using different doses. It does not 
lead to dependence, early or late withdrawal effects after 
discontinuation.51,77–79 The development of tolerance is usu-
ally absent with melatonin, although a few exceptions have 
been reported, especially in some children with neurological 
disorders.91–94 Should the development of tolerance turn out 
to be a consequence of altered metabolism, which remains 
to be demonstrated, other melatoninergic agonists might 
be tested. A recent randomized, double-blind, placebo-
controlled crossover study on prolonged-release melatonin 
confirmed the absence of next-day impairments of psychomo-
tor functions, driving skills and memory recall, in contrast 
to 10 mg zolpidem.109 Controlled-release melatonin (2 mg) 
was successfully used even for facilitating benzodiazepine 
discontinuation.110Neuropsychiatric Disease and Treatment 2009:5 349
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Like melatonin, ramelteon did not cause next-day 
hangover (as revealed by subjective feeling, psychomotor 
and cognitive tests, and ability to concentrate),105 rebound 
insomnia or other withdrawal effects, or development of 
tolerance or addiction.20–22,105 Under these conditions, both 
prolonged-release melatonin and ramelteon appear safe in 
short-term treatment, as may be assumed for other exclu-
sively melatoninergic drugs in general.
For subjective criteria of adverse effects, such as reports 
of nausea, digestive difficulties, headache or other pain, diz-
ziness, and mood, no substantial differences were detected 
between Circadin® and placebo, and frequently trends were 
detected even towards fewer subjective side effects in the 
melatonin groups.51 In this context, it should be also noted 
that considerably higher doses of melatonin, 300 mg/day 
enterally, were administered for up to 2 years to amyotrophic 
lateral sclerosis patients and found to be safe.111 Subjec-
tive reports of adverse effects showed that ramelteon 4 or 
8 mg was also well tolerated, with similar outcomes as for 
placebo.20,21,104–107
Precautions should be taken with both melatonin and 
ramelteon for other reasons. First, the use of a melatonin-
ergic agonist should be restricted to appropriate circadian 
phases in the evening, since it may cause drowsiness when 
taken during daytime and, in this case, may in fact impair 
psychomotor functions, including driving skills. While the 
use of hypnotics should anyway be restricted to bedtime, 
more specific precautions are related to the pleiotropy19,45 of 
melatonin. It is of utmost importance to keep in mind that 
melatonin is not just a hormone transmitting the darkness 
signal, and not only a regulator affecting the SCN, but rather 
influences numerous additional functions.19,43–45,49 Even for 
ramelteon, which may exclusively act on MT1 and MT2 recep-
tors (although this selectivity has not been demonstrated for 
the newly discovered binding sites), various effects beyond 
SCN modulaton and sleep promotion have to be expected. 
This would include influences on other hormones, and on 
the immune system, vasculature, and the gastrointestinal 
system. The possibility of undesired melatoninergic effects 
on the reproduction system may be a controversial issue. 
The respective influences of the hormone are without any 
doubt not comparable to those in seasonal breeders, but, 
on the other hand, earlier attempts to use melatonin as a 
contraceptive,112–114 suppressive effects on the GnRH pulse 
generator115 and deviations of melatonin in reproductive 
disorders116–118 have been seen as a caveat in the opinion 
of some investigators and also of EMEA.51 Especially in 
reproductive disorders, changes in melatonin may not be 
causative, but rather consequences of other anatomical or 
physiological disturbances. In perimenopausal women, 
effects of melatonin on LH, FSH and thyroid hormones 
were observed,119 whereas no changes were detected in LH, 
FSH, testosterone and inhibin-β in normal men subjected to 
long-term treatment with the pineal hormone.120 However, 
melatonin was also reported to decrease semen quality in 
two healthy men,121 but this study was conducted with a very 
small number of volunteers. Concerns because of changes in 
the reproductive system may be taken as a contraindication 
for treating children, adolescents and pregnant women 
with melatonin, as did EMEA in the case of Circadin®.51 
On the other hand, children, adolescents and young adults 
have been treated for considerable periods of time with the 
pineal hormone, without reports of undesired effects in the 
reproductive system.14,76,85,95,122–124 The position of EMEA, 
which has approved Circadin® only for subjects of 55 years 
and older,51 may appear unduly cautious, but EMEA intends 
to be cautious. Nevertheless, melatonin formulations or other 
melatoninergic drugs should be an option for children with 
severe and otherwise intractable neurological disorders.
Precautions are necessary in subjects with immunologi-
cal disorders, since melatonin is also a mainly stimulatory 
immunomodulator.19,45,49 Thus, melatoninergic drugs should 
generally not be prescribed to patients with autoimmune dis-
eases.51 With both melatonin and ramelteon, another caveat 
concerns drugs influencing cytochrome P450 enzymes, espe-
cially inhibitors of CYP1A2,20,47,48,51 such as fluvoxamine, 
which would lead to substantial rises in circulating melatonin 
and ramelteon as well. Additional specific precautions are 
listed for Circadin®, such as LAPP lactase deficiency and glu-
cose-galactose malabsorption,51 and for ramelteon concerning 
alcohol, high-fat diet and renal impairment.20,125
Another disorder that may be regarded as a contra-
indication against the use of melatoninergic agonists is 
Parkinson’s disease (PD). Contrary to findings in various 
animal models, melatonin has not been generally beneficial 
in PD patients, especially for disease progression, as sum-
marized earlier.6 More recently, PD has been interpreted as an 
endocrine disorder characterized by melatonin hyperplasia.126 
Correspondingly, clinical improvements have been obtained 
by melatonin antagonist treatment.127 Melatonin hyperplasia 
may also deserve attention in other diseases, eg, irritable 
bowel syndrome type II, in which an enhanced proliferation 
of melatonin and serotonin producing cells is observed, in 
conjunction with losses of other cell types.128
At recommended doses51 and even higher, melatonin 
is devoid of mutagenicity or carcinogenicity, but instead Neuropsychiatric Disease and Treatment 2009:5 350
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appears to be protective in this regard.38,44,49,55,129 The absence 
of genotoxicity and carcinogenicity is also reported for 
ramelteon.125 However, some reservations seem appropriate 
with this drug,20,21,47 since the no-effect level for induction of 
hepatic tumors in male mice was only three times the concen-
tration of the metabolite M-II measured after the therapeutic 
dose.125 Moreover, micronuclei formations were observed in 
Chinese hamster lung cells after metabolic activation.125 The 
naphthalenic compound agomelatine may require further 
toxicological studies.21,47 In this place, it should be empha-
sized that safety studies also have to consider the properties 
of the metabolites, which is not generally sufficiently done. 
For the metabolites of melatonin, one can state that they never 
attain high concentrations. Kynuric products, which may be 
relevant in tissues, have been reported to be protective rather 
than deleterious.38,44,129 More extensive studies on properties 
of metabolites are necessary for any of the synthetic mela-
toninergic drugs, including β-methyl-6-chloromelatonin, 
tasimelteon and agomelatine, in the last case also for the 
serotonin analog S 21517,21 and, most importantly, for the 
ramelteon metabolite M-II, because of the high concentra-
tions attained and its long half-life in the circulation.
In summary, both prolonged-release melatonin and ramelt-
eon are well tolerated and safe in the populations indicated 
by the respective approvals, and acceptable for short-term 
treatment. Experience with the extended high-dose melatonin 
treatment in ALS patients111 indicates that Circadin® may be 
safe even for prolonged treatment, whereas more studies would 
be required for ramelteon to be sure about this point.20,21,47
Conclusions, place in therapy
Melatonin and all synthetic melatoninergic drugs discussed 
here are capable of phase shifting the circadian pacemaker, 
and all of them can be expected to reduce sleep onset latency, 
with the exception of a certain number of nonresponders. In 
terms of toxicology, beyond the subjective reports on absence 
or presence of adverse effects, β-methyl-6-chloromelatonin, 
ramelteon, tasimelteon and agomelatine need further investi-
gation for long-term safety, particularly for tasimelteon, which 
is administered in relatively high doses of 20 or 50 mg,69 
compared with the much lower doses of ramelteon (8 mg) or 
melatonin (2 mg). The nonselective drug agomelatine may 
be useful in major depressive disorder,21,47 but, alternatively, 
combinations of classic antidepressants with z-drugs such as 
zolpidem extended-release may be likewise effective.130
With these reservations, all the chronobiotics, but more 
in particular, the approved hypnotics Circadin® (melatonin 
prolonged release) and Rozerem® (ramelteon), but presumably 
also the investigative drug tasimelteon,69 should be suitable for 
treating jet lag or other phase shifts, and also tractable forms 
of CRSDs, such as DSPS and FASPS. Beyond phase resetting, 
facilitation of sleep onset can be expected in mild types of 
CRDS-related insomnia. In this regard, one might, however, 
ask whether a prolonged-release formulation or a drug of 
longer half-life and higher receptor affinity is really needed. 
Sleep onset can be even promoted by 0.1 or 0.3 mg immediate-
release melatonin,20 so that a higher dose may not be required 
in these cases, nor prolonged release, longer half-life or higher 
receptor affinity. Circadin® or Rozerem® may be tested, if 
immediate-release melatonin fails.
The situation is different in primary chronic insomnia, in 
which a substantial support of sleep maintenance is required. 
In this disorder, statistically significant but still moderate 
effects of ramelteon have been reported,20–22,47,102–107 whereas 
prolonged-release melatonin would require substantiation of 
its efficacy. Such a comparison should, however, consider 
the differences in recommended doses. Although ramelteon 
has considerably higher receptor affinities and a relatively 
longer half-life, 4 or 8 mg are recommended, whereas 
only 2 mg of melatonin are present in a Circadin® tablet. 
It seems inappropriate to be extremely cautious with the 
natural compound melatonin, which is exceptionally well 
tolerated in the majority of individuals, but not to apply the 
same criteria to a longer-acting synthetic analog with higher 
receptor affinity.47
Treatment with melatoninergic agonists seems to be 
promising in another disorder, Smith-Magenis syndrome, 
which is characterized, apart from developmental and neu-
robehavioral abnormalities, by a largely inverted melatonin 
rhythm and sleep difficulties.87,88 In this case, a combina-
tion of a β1-adrenergic blocker in the morning, to suppress 
diurnal melatonin secretion, and melatonin in the evening 
has been applied with some success.89,90 In this congenital 
disease, a sustained high nocturnal level of melatonin would 
be of particular importance, which indicates the use of a 
prolonged-release formulation. Whether or not melatonin 
may be replaced by synthetic agonists such as ramelteon 
remains to be clarified and may depend on long-term safety. 
Other neurodevelopmental and neuropsychiatric disorders 
associated with sleep difficulties or CRSDs, which have 
been studied in children and young adults and are sometimes 
otherwise intractable,76,85,86,91–94 may be seen as an additional 
area of treatment, despite the reservations of EMEA.
Nevertheless, caution should go beyond the risks men-
tioned in the previous section, such as autoimmune diseases, 
Parkinson’s disease, coadministration of CYP inhibitors, Neuropsychiatric Disease and Treatment 2009:5 351
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and hepatic and renal diseases. Surveillance seems to be 
appropriate for the development and function of reproduc-
tive organs. Pregnancy would be another condition under 
which benefits and possible risks have to be weighed. These 
considerations should equally apply to melatonin prolonged 
or immediate-release, ramelteon and other melatoninergic 
drugs. Therefore, the decision by EMEA to approve 
Circadin® for subjects older than 54 years, along with a list 
of specific precautions, is a responsible one, although it may 
appear unduly cautious. The same criteria should be applied 
to ramelteon, and to other melatoninergic drugs that may be 
evaluated for approval.
Nevertheless, all melatoninergic drugs discussed are well 
tolerated in short-term treatment, and for the natural compound, 
melatonin, the same should be valid for long-term administra-
tion, except for the precautions mentioned above.
Melatonin and its synthetic analogs may be helpful even 
in other disorders, such as relieving sleep difficulties caused 
by benzodiazepine discontinuation110 and in chronic obstruc-
tive pulmonary disorder, in which ramelteon has been shown 
to be effective,131,132 and for which the same may be valid in 
the case of melatonin.98,133
In practical terms, sleep difficulties should first be tested 
for causes related to circadian dysfunction, in which immedi-
ate-release melatonin may already be effective, and Circadin® 
should be tried if the immediate-release formulation does 
not suffice. In cases of chronic primary insomnia, ramelt-
eon seems, according to current knowledge, slightly more 
promising than prolonged-release melatonin. If melatonin-
ergic drugs fail, z-drugs may be the better option. In patients 
of appropriate age and not belonging to a risk group, the 
general strategy may be to first test the natural compound, 
melatonin, because of its remarkable tolerability and safety, 
before other options are used.
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